ChemoMetec A/S (0DZ0)
London Exchange · UK · prices in DKK · close of 21 Oct 2026
Key indicators
| Last close | DKK 582.00 |
|---|---|
| 52-week range | 236.00 – 801.50 |
| Return, 1 month / 3 months | +12.6% / +40.7% |
| Return, 1 year / 3 years | −15.8% / +128.6% |
| Trend | Uptrend |
| RSI (14) | 62 |
| Volatility (1 year) | 72.7% |
| Worst drawdown (1 year) | -69.9% |
| Average daily value traded | 2.90M DKK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
ChemoMetec is a Danish company that makes automated instruments for counting and analysing cells. Its main products are cell counters and related analysis systems used to measure cell concentration and viability, along with the consumables and software that go with them. Customers include laboratories in the biopharmaceutical, life science and food and beverage industries, where accurate cell measurement matters for quality and process control. The company is based in Allerød, Denmark, and supplies its instruments and supporting products to customers internationally.
ChemoMetec A/S trades under the code 0DZ0 on the London Exchange in UK, with its price quoted in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
ChemoMetec A/S (0DZ0) trades on the London Exchange in UK. It last closed at DKK 582.00 on 21 October 2026.
Its price-based Market X-Ray is 53 out of 100 (a fair price profile), ranking 1,895 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 15.8% and over the last three months it rose 40.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 73 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 32.1% | ||
| From 52-week high | -27.4% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 40.7% | ||
| 6-month return | 76.8% | ||
| 12-month return, skipping the last month | -25.2% | ||
| Stability (higher is calmer) | 10 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 72.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -69.9% | ||
| Liquidity | 63 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.90M DKK | ||
| Zero-volume days | 6.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 3 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −0.6% |
|---|---|
| 1 month | +12.6% |
| 3 months | +40.7% |
| 6 months | +76.8% |
| 1 year | −15.8% |
| 3 years | +128.6% |
| 5 years | −32.6% |
Signals
| 50-day / 200-day average | 521.38 / 440.63 |
|---|---|
| Golden / death cross (60 days) | Golden, 23 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 44.36 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 10 Oct 2025 | DKK 7.0000 |
| 11 Oct 2024 | DKK 4.0000 |
| 13 Oct 2023 | DKK 6.0000 |
| 15 Oct 2021 | DKK 4.0000 |
| 9 Oct 2020 | DKK 1.5000 |
| 14 Jan 2020 | DKK 13.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.